Clinical trials: Hepatitis B， Chronic
Chronic Hepatitis B
Establishment of Retrospective and Prospective Multicenter Cohort for Chronic Hepatitis B
According to the World Health Organization about 1,400,000 deaths reported annually, are related to chronic liver disease. Chronic liver disease is very prevalent in South Korea, placing a large economic burden nationwide.
- Trial name
- NCT02263755
- Volunteers
- 476 people
- Sponsor
- Yonsei University
Chronic Hepatitis B
Hospital-Based Management of Patients With Chronic Hepatitis B Virus Infection
Since 2022, the Third Affiliated Hospital of Sun Yat-sen University has initiated the "Hot Wave Project", a comprehensive hepatitis B infection prevention and management system encompassing patient education, screening, referral…
- Trial name
- NCT06966908
- Testing
- Facilitate the referral of in-hospital chronic hepatitis B patients and provide treatment and follow-up in the infectious disease department., Assessment of patient-reported outcomes (PROs) in patients with chronic hepatitis B.
- Where
- 3 sites in China
- Volunteers
- 16,300 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Hepatitis B, Besifovir Dipivoxil Maleate
Switching From Tenofovir Disoproxil Fumarate to Besifovir Dipivoxil Maleate
A research study to observe the safety, efficacy and tolerability of switching from Tenofovir Disoproxil Fumarate to Besifovir dipivoxil maleate in patients with chronic hepatitis B
- Conditions
- Hepatitis B, Besifovir Dipivoxil Maleate, Tenofovir Disoproxil Fumarate
- Trial name
- NCT04202536
- Testing
- Besifovir Dipivoxil Maleate, Tenofovir disoproxil fumarate(TDF)
- Where
- South Korea
- Volunteers
- 152 people
- Sponsor
- IlDong Pharmaceutical Co Ltd
Hepatitis B, Chronic, Lipid Disorder
An Experimental Study on the Effect of Tenofovir Amibufenamide on Blood Lipid During Anti-HBV Treatment
In June 2021, Chinese Food and Drug Administration approved the launch of the self-developed new drug Tenofovir Amibufenamide(TMF). TMF is a new second generation of tenofovir(TFV) and its effect on blood lipids is unclear.
- Trial name
- NCT05398393
- Testing
- oral Tenofovir Amibufenamide 25mg each day, lipid lowering drugs (e.g. Atorvastatin and amlodipine.)
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Chronic Hepatitis B
Switch From Adefovir to Tenofovir in Chronic Hepatitis B for Suboptimal Response to Adefovir-based Combination Therapy
In Korea, the number of suboptimal responders to rescue combination therapy is also increasing. As a matter of fact, according to the investigations in Korea, HBV DNA undetectability at 48 weeks of adefovir and lamivudine…
- Trial name
- NCT01595633
- Testing
- Switching from adefovir (10mg/day) to tenofovir (300mg/day)
- Where
- South Korea
- Volunteers
- 124 people
- Sponsor
- Yonsei University
Chronic Hepatitis B
Adefovir Dipivoxil In Compensated Chronic Hepatitis B Patients
This study is designed to compare the efficacy and safety of adefovir dipivoxil 10 mg with lamivudine 100 mg in Japanese patients with compensated chronic hepatitis B over 52-week periods.
- Trial name
- NCT00316719
- Testing
- LAM group, ADV group
- Volunteers
- 105 people
- Sponsor
- GlaxoSmithKline
Hepatitis B, Chronic, Liver Fibrosis
Induction of Fibrosis Regression on Patients With Chronic Hepatitis B Infection
This study will examine whether 12 month treatment with entecavir(Baraclude®) has an effect on changes of liver stiffness measurement (LSM) and of hyaluronan measurement in patients with chronic hepatitis B infection.
- Trial name
- INFIRE (NCT01341106)
- Testing
- Treatment with entecavir(Baraclude®)
- Where
- Germany
- Volunteers
- 7 people
- Sponsor
- RWTH Aachen University
Hepatitis B
A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection
Patients with HBeAG positive, chronic HBV infection will receive either ARC-520 or placebo in combination with entecavir or tenofovir, and be evaluated for safety and efficacy.
- Trial name
- NCT02604212
- Testing
- ARC-520, entecavir, antihistamine
- Where
- 16 sites in China, Germany and 1 more
- Volunteers
- 32 people
- Sponsor
- Arrowhead Pharmaceuticals
Chronic Hepatitis, Liver Cirrhosis
Hepatocyte-specific Versus Extracellular Contrast Agents for Liver MRI: Prospective, Intra-individual Comparison of Diagnostic Performance for Hepatocellular Carcinoma
Adult patients with chronic hepatitis B and cirrhosis of any etiology who are found to have suspected liver cancer are potentially eligible for the study.
- Trial name
- NCT03892681
- Testing
- hepatocyte-specific contrast agent, extracellular contrast agent
- Where
- South Korea
- Volunteers
- 129 people
- Sponsor
- Yonsei University
Fibrosis, Liver
Platelets Indices and Its Role to Predict Liver Fibrosis in Patients With Chronic Hepatitis B Infection
Platelets indices and its role to predict liver Fibrosis in patients with chronic hepatitis B infection
- Trial name
- NCT05567614
- Testing
- Liver Fibroscan
- Where
- Egypt
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Assiut University
Hepatitis B
Real World Assessment of People Living With Chronic Hepatitis B in Australia
The REACH-B study establishes an observational cohort study of people living with chronic hepatitis B from a national network, including a diverse range of services, to characterise and monitor hepatitis B linkage to care and…
- Trial name
- REACH-B (NCT04914611)
- Testing
- No intervention
- Where
- 19 sites in Australia
- Volunteers
- 10,000 people
- Sponsor
- Kirby Institute
Hepatitis B, Hepatitis B, Chronic
HBsAg Declined Patients Follow-up Study
The goal of this observational study is to prospectively follow chronic hepatitis B patients who had HBsAg decline in the past 12 months prior to screening.
- Trial name
- NCT05977283
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Chronic Hepatitis b
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB06-036 in Subjects With Chronic Hepatitis B
CB06-036 is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Chronic Hepatitis B.
- Trial name
- NCT05828745
- Testing
- CB06-036
- Where
- 2 sites in China, New Zealand
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhimeng Biopharma, Inc.
Hepatitis B, Chronic
Drug Drug Interaction Study for EYP001 With Entecavir
This is a Phase 1, single-center, open-label, three subsequent dosing periods study to evaluate the drug-drug-interaction (DDI), pharmaco-kinetics (PK) and pharmacodynamics (PD), safety, and tolerability of a single dose of…
- Trial name
- NCT03469583
- Testing
- EYP001, Entecavir 1 MG
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Enyo Pharma
Chronic Hepatitis B
A Efficacy and Safety Study of Adefovir Dipivoxil to Treat Chinese Patients With HBeAg+ve Chronic Hepatitis B
The purpose of this study is to determine whether Adefovir Dipivoxil is effective and safe in treatment of Chinese Patients with HBeAg positive Chronic Hepatitis B for 5 years.
- Trial name
- NCT00857675
- Testing
- AAAA, AAPA, PAAA
- Where
- 10 sites in China
- Volunteers
- 480 people
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis B Infections
Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function
This Phase 1 non-randomized, open-label, single-dose hepatic impairment study consists of 2 cohorts, conducted in 16 subjects, 8 subjects with moderate hepatic impairment (Cohort 1) and 8 subjects without hepatic impairment…
- Trial name
- NCT07342868
- Testing
- Pevifoscorvir Sodium (ALG-000184)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Aligos Therapeutics
Hepatitis B Infection, Chronic Infection
Tenofovir in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus
Immunoprophylaxis failure of hepatitis B virus (HBV) leading to vertical transmission remains a concern and has been reported in approximately 8-15% of infants born to hepatitis B e antigen (HBeAg) positive mothers with high…
- Conditions
- Hepatitis B Infection, Chronic Infection, Viremia
- Trial name
- NCT01488526
- Testing
- TDF treatment
- Where
- 5 sites in China
- Volunteers
- 200 people
- Sponsor
- New Discovery LLC
Chronic Hepatitis B, Hepatic Steatosis
Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients
To investigate the influence of hepatic steatosis on the anti-viral effect of entecavir in chronic hepatitis B patients.
- Trial name
- NCT01148576
- Testing
- entecavir, essentiale + entecavir, Vitamin E + entecavir
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Zhejiang University
Hepatitis B
Durability of Antiviral Activity in Chronic HBV Patients Who Showed Complete Response in L-FMAU-301,302 or 303 Trial
The purpose of this study is to evaluate the durability of antiviral activity in chronic hepatitis B patients who showed complete response in L-FMAU-301,L-FMAU-302 or L-FMAU-303 trial.
- Trial name
- NCT00362674
- Where
- 27 sites in South Korea
- Sponsor
- Bukwang Pharmaceutical
Hepatitis B, Lymphoma
Tenofovir to Prevent HBV Reactivation
The purpose of the study is to determine how effective preemptive tenofovir therapy is in preventing the re-activation of Hepatitis B infection, in patients who are receiving rituximab-based chemotherapy for Non-Hodgkin's…
- Conditions
- Hepatitis B, Lymphoma, Non-Hodgkin
- Trial name
- NCT02186574
- Testing
- Tenofovir disoproxil
- Where
- 2 sites in Canada
- Volunteers
- 184 people
- Sponsor
- University Health Network, Toronto
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.